右美托咪定鞘内注射对慢性神经痛模型大鼠行为能力、疼痛程度和脊髓背角蛋白激酶C表达的影响

发布时间：2018-03-20 19:17

本文选题：鞘内注射　切入点：右美托咪定　出处：《中国比较医学杂志》2017年06期 　论文类型：期刊论文

【摘要】：目的分析右美托咪定鞘内注射对于慢性神经痛模型鼠的行为、疼痛程度脊髓背角蛋白激酶C(protein kinase C,即PKC)的影响,初步探讨右美托咪定的镇痛机制。方法将50只成功建立模型的大鼠随机分为观察组、模型组,另选取25只健康大鼠作为对照组,观察组和模型组大鼠建立慢性坐骨神经损伤模型,在建模后,观察组应用右美托咪定鞘内注射干预,模型组应用生理盐水注射,对照组不接受干预,在建模前、给药后3、5、7、14 d时分别进行行为能力评价(累积评分法和运动功能评价)和疼痛程度评价(机械性缩足反射法和热缩足反射潜伏期法检测痛阈值),同时进行PKC免疫染色评分(免疫组化SABC法)、PKCmRNA检测(RT-PCR法)和PKC蛋白(Western blot法)表达,利用统计方法分析组间数据。结果 (1)建模前,各组大鼠行为累积评分、运动功能评分、机械性缩足反射法(MWT)、热缩足反射潜伏期法(TWL)差异无显著性(P0.05),在建模后,模型组和观察组大鼠累积评分和运动功能评分显著升高,MWT和TWL明显下降,其中观察组变化幅度显著低于模型组,建模后,组间累积评分、运动功能评分、MWT、TWL具有明显差异(P0.05);(2)对照组PKC为阴性表达,模型组PKC呈强阳性表达,观察组建模后初期PKC为强阳性,随着治疗时间延长,PKC表达强度降低,第14天时PKC为弱阳性表达;(3)建模后,观察组和模型组PKCmRNA和PKC蛋白表达水平显著高于对照组(P0.05);随着不断给药,观察组PKCmRNA和PKC下降,在给药14 d时,PKCmRNA和PKC接近对照组,建模后3 d起,在相同时间点,观察组PKC表达量显著低于模型组(P0.05)。结论右美托咪定鞘内注射能够改善慢性神经痛模型大鼠行为能力、降低疼痛程度,可能与其抑制脊髓背角蛋白激酶C的表达相关。
[Abstract]:Objective to analyze the effects of intrathecal injection of dexmetomidine on the behavior and pain degree of spinal dorsal keratin kinase (kinase) in rats with chronic neuralgia. Methods 50 successful rats were randomly divided into observation group, model group and 25 healthy rats as control group. The model of chronic sciatic nerve injury was established in the observation group and the model group. After the model was established, the observation group was treated with dexmetomidine intrathecal injection, the model group was injected with normal saline, the control group did not receive the intervention, before modeling, the model group was treated with dexmetomidine intrathecal injection. The behavioral ability (cumulative score and motor function evaluation) and pain degree (mechanical foot reflex and thermal foot reflex latency) were evaluated at 14 days after administration. PKC immunostaining was performed at the same time. The expression of color score (immunohistochemistry, SABC, RT-PCR) and PKC protein (Western blot) were observed. Results: before modeling, there were no significant differences in the scores of behavior accumulation, motor function, mechanical foot reflex (MWTT) and thermal foot reflex latency (TWL) in each group, but there was no significant difference between the two groups after modeling. The cumulative score and motor function score of rats in the model group and the observation group were significantly increased, and the changes of MWT and TWL in the observation group were significantly lower than those in the model group, and the cumulative score between the groups after modeling was significantly lower than that in the observation group. Motor function score (MWTT TWL) the PKC expression in the control group was negative, the PKC expression in the model group was strongly positive, and the PKC expression in the observation group was strongly positive at the initial stage after modeling, and decreased with the prolongation of the treatment time. The expression levels of PKCmRNA and PKC protein in observation group and model group were significantly higher than those in control group (P 0.05), and PKCmRNA and PKC in observation group decreased with continuous administration, and were similar to those in control group at day 14. From 3 days after modeling, the expression of PKC in the observation group was significantly lower than that in the model group at the same time point. Conclusion the intrathecal injection of dexmetomidine can improve the behavioral ability and reduce the degree of pain in the chronic neuralgia model rats. It may be related to the inhibition of the expression of dorsal keratin C in spinal cord.
【作者单位】：海南医学院第二附属医院麻醉科;广州医科大学附属第四医院麻醉科;
【分类号】：R-332;R614

【相似文献】